SlideShare a Scribd company logo
1 of 1
Download to read offline
Persistent             Back on Index Therapy
                                                                                                                                                                                                           100
                                                             Progression
                                                                                                                                                                                                           90
                                                                                                                                                                                                           80
                                                                                         Compensatory expansion                             Expansion overcome:                                            70




                                                                                                                                                                                     Percent of Patients
                                                                                         maintains constant lumen                             lumen narrows
                                                                                                                                                                                                           60
                                                                                                                                                                                                           50
                                                                                                                                                                                                           40
                                                                                                                                                                                                           30
                                                                                                                                                                                                           20
                                                                                                                                                                                                           10
                                                              Normal                   Minimal                       Moderate                         Severe                                                0
                                                              vessel                    CAD                           CAD                              CAD
                                                                                                                                                                                                                 30   60                            90       120     150          180       210     240      270   300   330   360

                                                                                                                                                                                                                                                                              Days After Index


                                                                                                  illustration                                                                                                                                                                    area
                                                              100
                                                                                                                                                 Valsartan/HCTZ 320/12.5-25 mg
                                                               90                                                                                Valsartan/HCTZ 160/12.5-25 mg


                                                               80
                               Patients Achieving Goal (%)




                                                                                                                                                 Valsartan 320 mg
                                                                                                                                                 Valsartan/HCTZ 80/12.5 mg
                                                               70                                                                                Valsartan 160 mg


                                                               60
                                                                                                                                                 Valsartan 80 mg

                                                               50
                                                                                                                                                 Placebo
                                                               40

                                                               30

                                                               20

                                                               10

                                                               0
                                                                    0       7     14       21        28         35      42        49       56
                                                                                        Duration of Treatment (days)




                                                                                       Kaplan-Meier curve                                                                                                                                                                          line
                                                                                                                                          100%                 100%
Cumulative Percent of Allocated Vaccine




                                                             100                                                         93%                                                                                                                                            P2
                                                                                                                                                                                                                                                    160                                                   SBP
                                                                                                                                                                                                                                                             AP
                                                              80
                                                                                                                                                                                                                           Aortic Pressure (mmHG)

                                                                                                          72%                                                                                                                                                                                 PP
                                                                                                                             Cumulative percent of flu vaccine released                                                                             120            P1
                                                                                                                             by manufacturers
                                                                                                                                                                                                                                                                                                          MAP
                                                              60                                                             Demand for flu vaccine
                                                                                                                                                                                                                                                     80                                                   DBP

                                                              40                       36%

                                                                                                                                                                                                                                                     40                            AI = AP/PP
                                                              20
                                                                          10%

                                                                                                                                                                                                                                                         0
                                                               0                                                                                                                                                                                              Systole                   Diastole
                                                                         August   September          October           November December                     January
                                                                                                                                                                                                                                                                             DN

                                                                                                     line/area                                                                                                                                                               line/area

                                                                            Washout Phase                  Treatment Phase I                           Treatment Phase II                                                                           • Illustrations
                                                                                                            Diuretic 5 mg or
                                                                                                          Felodipine 5 mg (1:1)
                                                                                                                                                      Amlodipine 5 mg/
                                                                                                                                                      Diuretic 160 mg
                                                                                                                                                                                                                                                    • Bar, area, and pie charts
                                                                                                                                                                                                                                                    • Kaplan-Meier curves
      Visit                                                              1/2                     3                                           4                                   5                                                                  • Complex tables
      Week                                                              -2/-1                    0                                           4                                   8
                                                                                                                                                                                                                                                    • Flow charts
      Main
                                                                                       SBP ≥160 mm Hg
                                                                                                                                                                                                                                                    • Scatter graphs
      Inclusion                                                                                                                 SBP ≥140 mm Hg
      Criteria
                                                                                       and <180 mm Hg                                                                                                                                               • Study designs

                                                                                                 study design



                                                                                                                                       Data-Driven Medical Graphics
                                                                                                       31 Jane Street, 14E New York, NY 10014
                                                                                                212-675-9530 TEL • barbara.swenson@verizon.net E-MAIL

More Related Content

Similar to Swenson2010

Amax introduction and-data-center-presentation082211
Amax introduction and-data-center-presentation082211Amax introduction and-data-center-presentation082211
Amax introduction and-data-center-presentation082211Mike Ballard
 
North herts Homes - Lounge Bar
North herts Homes - Lounge BarNorth herts Homes - Lounge Bar
North herts Homes - Lounge BarCraig Taylor
 
Cim & brilliant media introduction to econometrics
Cim & brilliant media introduction to econometricsCim & brilliant media introduction to econometrics
Cim & brilliant media introduction to econometricsNeil Charles
 
A1 Bertrand
A1 BertrandA1 Bertrand
A1 Bertrandkrisjett
 
Crystal Reports-Running Times
Crystal Reports-Running TimesCrystal Reports-Running Times
Crystal Reports-Running Timesoaes2006
 
Corporate Presentation
Corporate PresentationCorporate Presentation
Corporate PresentationSySallard
 
Fools garden lemon tree
Fools garden   lemon treeFools garden   lemon tree
Fools garden lemon treeSah Ya
 
World Map - Asia
World Map - AsiaWorld Map - Asia
World Map - Asiaglassyglass
 
AC/DC highway to hell
AC/DC highway to hellAC/DC highway to hell
AC/DC highway to helldhan drummer
 
La Corda D'Oro: Brand New Breeze for Violin
La Corda D'Oro: Brand New Breeze for ViolinLa Corda D'Oro: Brand New Breeze for Violin
La Corda D'Oro: Brand New Breeze for Violinsayakahime
 
Az apache junction_oldwest_goldfield_brochure (1)
Az apache junction_oldwest_goldfield_brochure (1)Az apache junction_oldwest_goldfield_brochure (1)
Az apache junction_oldwest_goldfield_brochure (1)CProperties
 
CIIB Client Profile Jun 09
CIIB Client Profile Jun 09CIIB Client Profile Jun 09
CIIB Client Profile Jun 09Dax Basdeo
 
RMAWGEN: a software project for Daily Multi-Site Weather Generator
RMAWGEN: a software project for Daily Multi-Site Weather GeneratorRMAWGEN: a software project for Daily Multi-Site Weather Generator
RMAWGEN: a software project for Daily Multi-Site Weather GeneratorEmanuele Cordano
 
From local food movement actions to public policies.
From local food movement actions to public policies.From local food movement actions to public policies.
From local food movement actions to public policies.Ricard Espelt
 
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...CambridgeIP Ltd
 

Similar to Swenson2010 (20)

Amax introduction and-data-center-presentation082211
Amax introduction and-data-center-presentation082211Amax introduction and-data-center-presentation082211
Amax introduction and-data-center-presentation082211
 
North herts Homes - Lounge Bar
North herts Homes - Lounge BarNorth herts Homes - Lounge Bar
North herts Homes - Lounge Bar
 
Robert palmer
Robert palmerRobert palmer
Robert palmer
 
Cim & brilliant media introduction to econometrics
Cim & brilliant media introduction to econometricsCim & brilliant media introduction to econometrics
Cim & brilliant media introduction to econometrics
 
A1 Bertrand
A1 BertrandA1 Bertrand
A1 Bertrand
 
Crystal Reports-Running Times
Crystal Reports-Running TimesCrystal Reports-Running Times
Crystal Reports-Running Times
 
Corporate Presentation
Corporate PresentationCorporate Presentation
Corporate Presentation
 
Fools garden lemon tree
Fools garden   lemon treeFools garden   lemon tree
Fools garden lemon tree
 
Asia
AsiaAsia
Asia
 
Asia
AsiaAsia
Asia
 
World Map - Asia
World Map - AsiaWorld Map - Asia
World Map - Asia
 
AC/DC highway to hell
AC/DC highway to hellAC/DC highway to hell
AC/DC highway to hell
 
La Corda D'Oro: Brand New Breeze for Violin
La Corda D'Oro: Brand New Breeze for ViolinLa Corda D'Oro: Brand New Breeze for Violin
La Corda D'Oro: Brand New Breeze for Violin
 
Az apache junction_oldwest_goldfield_brochure (1)
Az apache junction_oldwest_goldfield_brochure (1)Az apache junction_oldwest_goldfield_brochure (1)
Az apache junction_oldwest_goldfield_brochure (1)
 
CIIB Client Profile Jun 09
CIIB Client Profile Jun 09CIIB Client Profile Jun 09
CIIB Client Profile Jun 09
 
Egu 2012 cordano_eccel
Egu 2012 cordano_eccelEgu 2012 cordano_eccel
Egu 2012 cordano_eccel
 
RMAWGEN: a software project for Daily Multi-Site Weather Generator
RMAWGEN: a software project for Daily Multi-Site Weather GeneratorRMAWGEN: a software project for Daily Multi-Site Weather Generator
RMAWGEN: a software project for Daily Multi-Site Weather Generator
 
Egu 2012 cordano_eccel
Egu 2012 cordano_eccelEgu 2012 cordano_eccel
Egu 2012 cordano_eccel
 
From local food movement actions to public policies.
From local food movement actions to public policies.From local food movement actions to public policies.
From local food movement actions to public policies.
 
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...
Technology Transfer in the Renewable Energy Space: Key Challenges and Opportu...
 

Recently uploaded

Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365
Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365
Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 3652toLead Limited
 
Unblocking The Main Thread Solving ANRs and Frozen Frames
Unblocking The Main Thread Solving ANRs and Frozen FramesUnblocking The Main Thread Solving ANRs and Frozen Frames
Unblocking The Main Thread Solving ANRs and Frozen FramesSinan KOZAK
 
Next-generation AAM aircraft unveiled by Supernal, S-A2
Next-generation AAM aircraft unveiled by Supernal, S-A2Next-generation AAM aircraft unveiled by Supernal, S-A2
Next-generation AAM aircraft unveiled by Supernal, S-A2Hyundai Motor Group
 
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...HostedbyConfluent
 
Install Stable Diffusion in windows machine
Install Stable Diffusion in windows machineInstall Stable Diffusion in windows machine
Install Stable Diffusion in windows machinePadma Pradeep
 
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...Neo4j
 
The Codex of Business Writing Software for Real-World Solutions 2.pptx
The Codex of Business Writing Software for Real-World Solutions 2.pptxThe Codex of Business Writing Software for Real-World Solutions 2.pptx
The Codex of Business Writing Software for Real-World Solutions 2.pptxMalak Abu Hammad
 
IAC 2024 - IA Fast Track to Search Focused AI Solutions
IAC 2024 - IA Fast Track to Search Focused AI SolutionsIAC 2024 - IA Fast Track to Search Focused AI Solutions
IAC 2024 - IA Fast Track to Search Focused AI SolutionsEnterprise Knowledge
 
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhi
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | DelhiFULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhi
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhisoniya singh
 
Maximizing Board Effectiveness 2024 Webinar.pptx
Maximizing Board Effectiveness 2024 Webinar.pptxMaximizing Board Effectiveness 2024 Webinar.pptx
Maximizing Board Effectiveness 2024 Webinar.pptxOnBoard
 
Benefits Of Flutter Compared To Other Frameworks
Benefits Of Flutter Compared To Other FrameworksBenefits Of Flutter Compared To Other Frameworks
Benefits Of Flutter Compared To Other FrameworksSoftradix Technologies
 
Human Factors of XR: Using Human Factors to Design XR Systems
Human Factors of XR: Using Human Factors to Design XR SystemsHuman Factors of XR: Using Human Factors to Design XR Systems
Human Factors of XR: Using Human Factors to Design XR SystemsMark Billinghurst
 
Slack Application Development 101 Slides
Slack Application Development 101 SlidesSlack Application Development 101 Slides
Slack Application Development 101 Slidespraypatel2
 
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024BookNet Canada
 
SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024Scott Keck-Warren
 
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024BookNet Canada
 
Advanced Test Driven-Development @ php[tek] 2024
Advanced Test Driven-Development @ php[tek] 2024Advanced Test Driven-Development @ php[tek] 2024
Advanced Test Driven-Development @ php[tek] 2024Scott Keck-Warren
 

Recently uploaded (20)

Vulnerability_Management_GRC_by Sohang Sengupta.pptx
Vulnerability_Management_GRC_by Sohang Sengupta.pptxVulnerability_Management_GRC_by Sohang Sengupta.pptx
Vulnerability_Management_GRC_by Sohang Sengupta.pptx
 
Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365
Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365
Tech-Forward - Achieving Business Readiness For Copilot in Microsoft 365
 
Unblocking The Main Thread Solving ANRs and Frozen Frames
Unblocking The Main Thread Solving ANRs and Frozen FramesUnblocking The Main Thread Solving ANRs and Frozen Frames
Unblocking The Main Thread Solving ANRs and Frozen Frames
 
Next-generation AAM aircraft unveiled by Supernal, S-A2
Next-generation AAM aircraft unveiled by Supernal, S-A2Next-generation AAM aircraft unveiled by Supernal, S-A2
Next-generation AAM aircraft unveiled by Supernal, S-A2
 
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...
Transforming Data Streams with Kafka Connect: An Introduction to Single Messa...
 
Install Stable Diffusion in windows machine
Install Stable Diffusion in windows machineInstall Stable Diffusion in windows machine
Install Stable Diffusion in windows machine
 
The transition to renewables in India.pdf
The transition to renewables in India.pdfThe transition to renewables in India.pdf
The transition to renewables in India.pdf
 
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...
Neo4j - How KGs are shaping the future of Generative AI at AWS Summit London ...
 
The Codex of Business Writing Software for Real-World Solutions 2.pptx
The Codex of Business Writing Software for Real-World Solutions 2.pptxThe Codex of Business Writing Software for Real-World Solutions 2.pptx
The Codex of Business Writing Software for Real-World Solutions 2.pptx
 
IAC 2024 - IA Fast Track to Search Focused AI Solutions
IAC 2024 - IA Fast Track to Search Focused AI SolutionsIAC 2024 - IA Fast Track to Search Focused AI Solutions
IAC 2024 - IA Fast Track to Search Focused AI Solutions
 
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhi
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | DelhiFULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhi
FULL ENJOY 🔝 8264348440 🔝 Call Girls in Diplomatic Enclave | Delhi
 
Maximizing Board Effectiveness 2024 Webinar.pptx
Maximizing Board Effectiveness 2024 Webinar.pptxMaximizing Board Effectiveness 2024 Webinar.pptx
Maximizing Board Effectiveness 2024 Webinar.pptx
 
Benefits Of Flutter Compared To Other Frameworks
Benefits Of Flutter Compared To Other FrameworksBenefits Of Flutter Compared To Other Frameworks
Benefits Of Flutter Compared To Other Frameworks
 
Human Factors of XR: Using Human Factors to Design XR Systems
Human Factors of XR: Using Human Factors to Design XR SystemsHuman Factors of XR: Using Human Factors to Design XR Systems
Human Factors of XR: Using Human Factors to Design XR Systems
 
Slack Application Development 101 Slides
Slack Application Development 101 SlidesSlack Application Development 101 Slides
Slack Application Development 101 Slides
 
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
#StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
 
SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024SQL Database Design For Developers at php[tek] 2024
SQL Database Design For Developers at php[tek] 2024
 
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
Transcript: #StandardsGoals for 2024: What’s new for BISAC - Tech Forum 2024
 
E-Vehicle_Hacking_by_Parul Sharma_null_owasp.pptx
E-Vehicle_Hacking_by_Parul Sharma_null_owasp.pptxE-Vehicle_Hacking_by_Parul Sharma_null_owasp.pptx
E-Vehicle_Hacking_by_Parul Sharma_null_owasp.pptx
 
Advanced Test Driven-Development @ php[tek] 2024
Advanced Test Driven-Development @ php[tek] 2024Advanced Test Driven-Development @ php[tek] 2024
Advanced Test Driven-Development @ php[tek] 2024
 

Swenson2010

  • 1. Persistent Back on Index Therapy 100 Progression 90 80 Compensatory expansion Expansion overcome: 70 Percent of Patients maintains constant lumen lumen narrows 60 50 40 30 20 10 Normal Minimal Moderate Severe 0 vessel CAD CAD CAD 30 60 90 120 150 180 210 240 270 300 330 360 Days After Index illustration area 100 Valsartan/HCTZ 320/12.5-25 mg 90 Valsartan/HCTZ 160/12.5-25 mg 80 Patients Achieving Goal (%) Valsartan 320 mg Valsartan/HCTZ 80/12.5 mg 70 Valsartan 160 mg 60 Valsartan 80 mg 50 Placebo 40 30 20 10 0 0 7 14 21 28 35 42 49 56 Duration of Treatment (days) Kaplan-Meier curve line 100% 100% Cumulative Percent of Allocated Vaccine 100 93% P2 160 SBP AP 80 Aortic Pressure (mmHG) 72% PP Cumulative percent of flu vaccine released 120 P1 by manufacturers MAP 60 Demand for flu vaccine 80 DBP 40 36% 40 AI = AP/PP 20 10% 0 0 Systole Diastole August September October November December January DN line/area line/area Washout Phase Treatment Phase I Treatment Phase II • Illustrations Diuretic 5 mg or Felodipine 5 mg (1:1) Amlodipine 5 mg/ Diuretic 160 mg • Bar, area, and pie charts • Kaplan-Meier curves Visit 1/2 3 4 5 • Complex tables Week -2/-1 0 4 8 • Flow charts Main SBP ≥160 mm Hg • Scatter graphs Inclusion SBP ≥140 mm Hg Criteria and <180 mm Hg • Study designs study design Data-Driven Medical Graphics 31 Jane Street, 14E New York, NY 10014 212-675-9530 TEL • barbara.swenson@verizon.net E-MAIL